Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05320159 · ClinicalTrials.gov registry record
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 17,743
- Enrollment target
NCT05320159 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 17,743 participants.
The verdict
NCT05320159 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 17,743 participants
- Enrollment target
Study Summary
This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.
Interventions
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,743 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2021-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05320159
The ClinicalTrials.gov registry entry for NCT05320159 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17,743 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Secukinumab is the first listed.
NCT05320159 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05320159 about?
NCT05320159 is a clinical study titled "Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)". This was a retrospective cohort study utilizing data from Modernizing Medicine Data Services' (MMDS) electronic medical records (EMR)-based dermatology database to evaluate secukinumab patient characteristics, treatment patterns, and outcomes.
What is the current status of trial NCT05320159?
This trial is currently completed. The enrollment target is 17,743 participants. The study started on 2021-02-03. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT05320159?
The interventions under investigation include: Secukinumab (DRUG).
Who is sponsoring clinical trial NCT05320159?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.